For research use only. GLP-1 receptor agonist peptides including Semaglutide and Tirzepatide are discussed here strictly as research compounds. These are not approved by Iron Labs for human use and are sold exclusively for laboratory research.
The Science of GLP-1 Receptor Research
Glucagon-like peptide-1 (GLP-1) is an incretin hormone naturally secreted from intestinal L-cells in response to nutrient intake. Its receptor, GLP-1R, is expressed across multiple tissue types including the pancreas, brain, heart, and kidneys, making it a target of substantial academic and pharmaceutical research interest. The development of synthetic GLP-1 receptor agonist peptides has been one of the most significant areas of metabolic biology research over the past two decades.
Key GLP-1 Peptides Under Research Investigation
Semaglutide
Semaglutide is a long-acting GLP-1 receptor agonist with a half-life of approximately 7 days, achieved through fatty acid conjugation enabling albumin binding. In research models, Semaglutide has been studied extensively in the context of pancreatic beta-cell function, central appetite signaling, and cardiovascular risk biomarkers. Its molecular structure incorporates substitutions at positions 8 and 34 of native GLP-1 to resist DPP-4 degradation.
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist, representing a newer class of metabolic research peptide. Its dual-agonist mechanism has generated substantial research interest due to observed additive effects on insulin secretion pathways and appetite-regulating neuronal circuits in preclinical models. Studies have examined its influence on adipose tissue biology, hepatic lipid metabolism, and energy expenditure signaling.
Retatrutide
Retatrutide is a triple receptor agonist (GLP-1/GIP/glucagon) currently in advanced clinical trials. Preclinical research has examined its role in simultaneous modulation of three incretin/metabolic pathways, creating interest in its potential implications for energy homeostasis research models.
Cagrilintide
Cagrilintide is a long-acting amylin analogue studied in combination with Semaglutide in clinical research settings. Amylin receptors are expressed in the central nervous system and play a role in satiety signaling research, distinct from GLP-1 pathways but often co-investigated in metabolic biology studies.
Research Applications Overview
| Compound | Receptor Target(s) | Primary Research Areas | Half-Life |
|---|---|---|---|
| Semaglutide | GLP-1R | Metabolic signaling, beta-cell biology | ~7 days |
| Tirzepatide | GLP-1R + GIPR | Dual incretin pathways, adipose biology | ~5 days |
| Retatrutide | GLP-1R + GIPR + GcgR | Triple receptor agonism, energy homeostasis | ~6 days |
| Cagrilintide | Amylin receptors | Central satiety signaling, combination models | ~7 days |
Laboratory Handling Notes
GLP-1 class peptides are typically supplied as lyophilized powder. Reconstitute with bacteriostatic water using sterile technique. Store lyophilized stock at -20°C; reconstituted solutions at 2–8°C for up to 28 days. These peptides are sensitive to light and repeated freeze-thaw cycles. All Iron Labs GLP-1 peptides include COA documentation with HPLC and mass spec data.
Source GLP-1 research peptides from Iron Labs → Iron Labs Metabolic Peptide Catalog
Regulatory Notice
Semaglutide, Tirzepatide, Retatrutide, and Cagrilintide are sold by Iron Labs exclusively as research chemicals for laboratory use. These compounds are not sold or intended for human therapeutic use. Iron Labs makes no health claims. Researchers are responsible for compliance with all applicable regulations in their jurisdiction.